Evidence map›Paper›PMID 39673042›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Multidisciplinary treatment of a rare rapidly progressive intracranial myxoid mesenchymal tumor of uncertain differentiation FET-CREB fusion-negative.

Flavio Panico, Andrea Bianconi, Luca Bertero, Rosa Palmiero, Pietro Zeppa, Alessia Andrea Ricci, Luca Mangherini, Fabio Cofano, Roberta Rudà, Diego Garbossa and 1 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Flavio PanicoNeurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy. flavio.panico@unito.it.ORCID http://orcid.org/0009-0009-2800-5384
Andrea BianconiNeurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Luca BerteroPathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Rosa PalmieroNeuro-Oncology Unit, Department of Neuroscience, University of Turin, Turin, Italy.
Pietro ZeppaNeurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Alessia Andrea RicciPathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Luca MangheriniPathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Fabio CofanoNeurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Roberta RudàNeuro-Oncology Unit, Department of Neuroscience, University of Turin, Turin, Italy.
Diego GarbossaNeurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Francesco ZengaNeurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-meningothelial intracranial mesenchymal tumors are a heterogeneous group of central nervous system neoplasms endowed with great variability clinically and histologically. For this precise reason, significant difficulties exist in specifically cataloguing tumor entities with such distant characteristics and such uncertain clinical course. CASE DESCRIPTION: In an attempt to increase the knowledge inherent in this type of central nervous system lesions we report a case of a rare and unusual myxoid mesenchymal tumor of difficult anatomopathological classification characterized by rapid progression and optimal therapeutic response after combined surgical and radiotherapy treatment, with histo-molecular definition and DNA methylation profile. In this case, multidisciplinary management led to timely surgical intervention based on the rapid clinical deterioration and radiological progression; after adjuvant therapy with hadron therapy, the patient has no signs of recurrence two years after the surgical procedure. No FET-CREB fusion was detected, and the DNA methylation profile suggested the presence of multiple chromosomal gains and losses.

conclusionsThe molecular definition as well the optimal therapeutic regimen of these tumors is not clearly defined yet and analysis of larger series is strongly warranted.

Indexed as

Brain NeoplasmsCombined Modality TherapyCyclic AMP Response Element-Binding ProteinDisease ProgressionDNA MethylationHumansMagnetic Resonance ImagingCyclic AMP Response Element-Binding ProteinAngiomatoid fibrous histiocytoma (AFH)FET-CREB fusionIntracranial myxoid mesenchymal tumor (IMMT)Mesenchymal non-meningothelial tumorsMyxoid tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.